| --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Advanced Technology for Better Drug Delivery Options | | | | | | | | | Corporate Investor Presentation | | | | | | | SAFE HARBOR STATEMENT 2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document contains forward-looking state ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q4 2020 Earnings Conference Call March 10, 2021 4:30 PM ET Company Participants Paul Sagan - Investor Relations Glenn Mattes - President & Chief Executive Officer Dale Christensen - Director, Clinical Development Kirk Coleman - Chief Financial Officer Bill Williams - Professor, University of Texas, Austin Chris Cano - Chief Operating Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Boobalan Pachaiyappan - H.C. Wainwright Mayank Mamtani - B ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39102 TFF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 82-4344737 (State or Other Jurisdiction of Incorporat ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Paul Sagan - Investor Relations Glenn Mattes - President and Chief Executive Officer Kirk Coleman - Chief Financial Officer Dale Christensen - Director, Clinical Development Chris Cano - Chief Operating Officer Bill Williams - Professor, University of Texas, Austin Conference Call Participants Jonathan Aschoff - ROTH Daniel Carlson - Tailwinds Research William Morrison - National Securit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-39102 TFF PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

| --- | --- | --- | --- | |------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Advanced Technology | | | | | for Better Drug Delivery Options | | | | | May 2020 Corporate Investor Presentation | | | | | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2020 Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants Paul Sagan - Investor Relations Glenn Mattes - President and Chief Executive Officer Kirk Coleman - Chief Financial Officer Chris Cano - Vice President-Business Development Bill Williams - University of Texas, Austin Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Daniel Carlson - Tailwinds Research Operator Good afternoon, ladies and gentlemen, and welcome to the TF ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 (Address of principal executive offices, including zip code) (737) 802-1973 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-39102 TFF PHARMACEUTICALS, INC. (Exact name of registrant as ...

| --- | --- | --- | --- | |------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Advanced Technology | | | | | for Better Drug Delivery Options | | | | | April 2020 Virtual Investor Summit | | | | | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q1 2020 Earnings Conference Call May 14, 2020 5:00 PM ET Company Participants Paul Sagan – Investor Relations Glenn Mattes – President and Chief Executive Officer Kirk Coleman – Chief Financial Officer Chris Cano – Vice President-Business Development Conference Call Participants Jonathan Aschoff – ROTH Capital Partners Douglas Russell – Brown Harris Stevens Bill Morrison – National Securities Operator Good afternoon, ladies and gentlemen, and welcome to the TFF Pharma ...